Also, pre-treating MSCs with, or combining MSCs treatments with growth factors such as VEGF 36,37, FGF-2 38 and tumour necrosis factor-α 38, have been shown to promote MSCs adhesion, survival and therapeutic potency in MI. This evidence concerns the gene VEGFA and myocardial infarction.